Overview Technical Risk & rank Quality Results Accounts Filings Guidance & governance
Guidance tracker
What POLYMED guided, and what came next
| Filed | What the filing says | Next results: profit YoY | Revenue | Move on the day |
|---|---|---|---|---|
| 11 Nov 2026 | Poly Medicure filed the transcript of its Q2 and H1 FY27 earnings conference call held on 05 November 2026, on unaudited results for the quarter and half year ended 30 September 2026. Management said H1 standalone revenue was INR919 crores (up 15%) with PAT of INR180 crores; Q2 standalone revenue was INR488 crores... NSE copy | No results filed since | ||
| 05 Nov 2026 | Poly Medicure Limited filed its investor presentation on unaudited standalone and consolidated financial results for the second quarter ended September 30, 2026, under Regulation 30 and Regulation 51 of the SEBI Listing Regulations. Consolidated FY26 operating revenue was Rs 1,875 crore, with India at Rs 997 crore,... NSE copy | No results filed since | ||
| 14 Aug 2026 | Poly Medicure submitted the transcript of its Q1 FY27 earnings conference call held on 10 August 2026, on unaudited results for the quarter ended 30 June 2026 (board approval 7 August 2026). Management said standalone revenue for Q1 was INR431 crores, up 12.3%, and consolidated revenue was INR525 crores, up 30.3%... NSE copy | +3.6 % | +30.8 % | +0.6 % |
| 29 May 2026 | Poly Medicure filed the transcript of its Q4 and FY26 earnings conference call held on 25 May 2026 on the audited results for the quarter and year ended 31 March 2026. Management said FY26 consolidated revenue grew 12.3% to INR1,875 crores and Q4 consolidated revenue was INR534 crores, up around 21% year-on-year;... NSE copy | -7.6 % | +30.3 % | +4.6 % |
| 25 May 2026 | Revised Investor's Presentation filed on Q4 and FY26 audited standalone and consolidated financial results (year ended March 31, 2026). Standalone FY26 revenue Rs 1,662.5 crore (FY25: Rs 1,601.8 crore); standalone FY26 operating EBITDA margin 27.8%, with Q4 FY26 standalone revenue Rs 443.0 crore. Consolidated FY26... NSE copy | -7.6 % | +30.3 % | +4.6 % |
| 07 Mar 2026 | Poly Medicure Limited filed its updated Investor Presentation (March 2026) with BSE and NSE under Regulations 30 and 51 of the SEBI LODR Regulations, also posted on the company website. The presentation describes the group as having 15 manufacturing plants in 5 countries, 390+ patents granted, 950+ distributors and... NSE copy | -27.8 % | +21.3 % | -6.9 % |
| 11 Feb 2026 | Poly Medicure filed the transcript of its Q3 and 9M FY26 earnings conference call held on 6 February 2026, on unaudited standalone and consolidated results for the quarter and nine months ended 31 December 2025. Management reported Q3 consolidated revenue of INR494 crores (up about 16.4% year-on-year), consolidated... NSE copy | -27.8 % | +21.3 % | -6.9 % |
| 05 Feb 2026 | Poly Medicure Limited filed its Q3 and 9M FY26 investor presentation (unaudited standalone and consolidated results for quarter and nine months ended December 31, 2025) with BSE and NSE. Consolidated Q3 FY26 revenue growth was 16.4%, with Q3 Operating EBITDA margin of 24.2% and standalone Q3 EBITDA margin of 26.8%.... NSE copy | -27.8 % | +21.3 % | -6.9 % |
| 14 Nov 2025 | Poly Medicure filed the transcript of its Q2 and H1 FY26 earnings conference call held on 10 November 2025, on unaudited standalone and consolidated results approved by the Board on 8 November 2025. Management said Q2 consolidated revenue was Rs. 444 crores (up about 5.7% year-on-year) with operating EBITDA margin... NSE copy | -16.8 % | +16.4 % | -7.5 % |
| 08 Nov 2025 | Poly Medicure filed its investor presentation on unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (Q2 FY26). Consolidated Q2 FY26 revenue was Rs 443.9 Crs, up 5.7% year on year (Q2 FY25: Rs 420.0 Crs); H1 FY26 revenue was Rs 847.1 Crs versus Rs 804.8 Crs... NSE copy | -16.8 % | +16.4 % | -7.5 % |
| 01 Oct 2025 | Poly Medicure Limited filed the transcript of its investor/analyst conference call held on 25 September 2025 on the proposed acquisition of the Citieffe Group, approved by the Board on 24 September 2025. Management said the company is acquiring 100% of MediStream (Swiss corporation holding Citieffe SRL, Bologna) at... NSE copy | +5.0 % | +5.7 % | -1.7 % |
| 09 Sep 2025 | Poly Medicure filed the transcript of its investor/analyst conference call held on 04 September 2025 on the proposed acquisition of PendraCare Group (Netherlands), approved by the Board on 03 September 2025. Management said the target had CY24 revenue of about EUR9.9 million, EBITDA of EUR1.4 million, PBT of about... NSE copy | +5.0 % | +5.7 % | -1.7 % |
| 14 Aug 2025 | Poly Medicure filed the transcript of its Q1 FY26 earnings conference call, held on 08 August 2025, on unaudited standalone and consolidated results for the quarter ended 30 June 2025. Management reported consolidated revenue of Rs. 403 crores, up about 5%, with gross margin of 68.4% and EBITDA of Rs. 106 crores... NSE copy | +5.0 % | +5.7 % | -1.7 % |
| 08 Aug 2025 | Poly Medicure filed its investor presentation on unaudited standalone and consolidated financial results for the quarter ended June 30, 2025 (Q1 FY26). Consolidated revenue rose 4.8% to Rs 403.2 crore from Rs 384.8 crore a year earlier; domestic revenue grew 20.1%. Consolidated operating EBITDA rose 2.1% to Rs... NSE copy | +5.0 % | +5.7 % | -1.7 % |
| 13 May 2025 | Poly Medicure filed the transcript of its Q4 FY25 earnings conference call held on 7 May 2025, on audited results for the quarter and year ended 31 March 2025. Management said consolidated revenue for Q4 was Rs. 440 crores, up about 16.5%, with PAT of Rs. 91.8 crores against Rs. 68.4 crores a year earlier;... NSE copy | +25.7 % | +4.8 % | +2.4 % |
| 10 Feb 2025 | Poly Medicure submitted the transcript of its Q3 FY25 earnings conference call held on 03 February 2025 (16:30 IST), covering unaudited standalone and consolidated results for the quarter and nine months ended 31 December 2024. Management said consolidated revenue for Q3 FY25 rose about 24.9% to Rs. 424 crores from... NSE copy | +34.3 % | +16.6 % | +1.9 % |
Filings tagged as guidance, newest first (16 in all), with the company's next results after each: profit and revenue against the same quarter a year before, and the share's move on the results day. Whether the guidance was met is for the reader to judge from both; the site does not score it. The summaries are written by an AI model from the filing and can be wrong - the filing is the source.
Governance
Management, auditors, ratings and legal matters
| Filed | Kind | What the filing says |
|---|---|---|
| 05 Nov 2026 | Legal or regulatory | Poly Medicure Limited's board approved unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2026, with Auditors' Review Reports attached as Annexure A. The board classified Poly Medicure B.V., Netherlands, a wholly owned subsidiary, as a Material Subsidiary of the... NSE copy |
| 14 Aug 2026 | Management change | Poly Medicure submitted the transcript of its Q1 FY27 earnings conference call held on 10 August 2026, on unaudited results for the quarter ended 30 June 2026 (board approval 7 August 2026). Management said standalone revenue for Q1 was INR431 crores, up 12.3%, and consolidated revenue was INR525 crores, up 30.3%... NSE copy |
| 07 Aug 2026 | Management change | Board of Poly Medicure Limited, at its meeting held on 07 August 2026 in Jaipur, approved unaudited standalone and consolidated financial results for the quarter ended 30 June 2026. Standalone total income for Q1 FY27 was Rs 45,974.91 lakh and standalone profit after tax was Rs 8,812.33 lakh; consolidated total... NSE copy |
| 26 Jun 2026 | Credit rating | Poly Medicure Limited filed an intimation under Regulation 30 of the SEBI LODR Regulations, 2015, disclosing credit ratings assigned or reaffirmed by CRISIL Ratings Limited. CRISIL Ratings, in a letter dated June 25, 2026, revised the long-term rating outlook to Positive from Stable and reaffirmed the long-term... NSE copy |
| 11 Feb 2026 | Legal or regulatory | Poly Medicure filed the transcript of its Q3 and 9M FY26 earnings conference call held on 6 February 2026, on unaudited standalone and consolidated results for the quarter and nine months ended 31 December 2025. Management reported Q3 consolidated revenue of INR494 crores (up about 16.4% year-on-year), consolidated... NSE copy |
| 05 Feb 2026 | Management change | Poly Medicure Limited's board approved the unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025, with Auditors' Review Reports attached. The board also approved the grant of 2,000 stock options to eligible employees under the Poly Medicure Limited Employee... NSE copy |
| 20 Aug 2025 | Legal or regulatory | Poly Medicure Limited filed a Regulation 30 disclosure that the NCLT Allahabad Bench, by order dated August 12, 2025, approved its resolution plan for acquiring Himalayan Mineral Waters Private Limited under the insolvency resolution process. The total consideration for acquiring the target is INR 33.15 crore, paid... NSE copy |
| 14 Aug 2025 | Management change | Poly Medicure filed the transcript of its Q1 FY26 earnings conference call, held on 08 August 2025, on unaudited standalone and consolidated results for the quarter ended 30 June 2025. Management reported consolidated revenue of Rs. 403 crores, up about 5%, with gross margin of 68.4% and EBITDA of Rs. 106 crores... NSE copy |
| 08 Aug 2025 | Legal or regulatory, Management change | Board meeting outcome dated 08 August 2025: unaudited standalone and consolidated financial results for the quarter ended 30 June 2025 approved, with an unmodified limited review report from statutory auditors. Standalone total income for Q1 FY26 was Rs 42,514.22 lacs (Rs 38,425.62 lacs in the year-ago quarter) and... NSE copy |
| 08 Aug 2025 | Legal or regulatory, Management change | Board meeting outcome dated 08 August 2025: unaudited standalone and consolidated financial results for the quarter ended 30 June 2025 approved, with an unmodified limited review report from statutory auditors. Standalone total income for Q1 FY26 was Rs 42,514.22 lacs and profit after tax Rs 8,792.89 lacs;... NSE copy |
| 06 May 2025 | Legal or regulatory, Management change | Board of Poly Medicure Limited, meeting held 06 May 2025, approved audited standalone and consolidated financial results for Q4 and FY ended 31 March 2025. The Board recommended a dividend of Rs. 3.50 per equity share (70%) of Rs. 5 each for FY 2024-25, subject to shareholder approval. The Board approved... NSE copy |
| 06 May 2025 | Legal or regulatory, Management change | Board of Poly Medicure Limited, meeting held on 06 May 2025, approved audited standalone and consolidated financial results for Q4 and financial year ended 31 March 2025. The Board recommended a dividend of Rs. 3.50 per equity share (70%) of Rs. 5 each for FY 2024-25, subject to shareholder approval. The Board... NSE copy |
Filings with a management change, a legal or regulatory matter or a credit rating (by their tags), or naming an auditor, a resignation or a pledge of shares; newest first (12 in all). A list of what was filed, not a judgement of the company.